TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04364672
Drug: 18F-labeled DPA-714 PET scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
Study: NCT05026229
Drug: dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
Study: NCT04791969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Oral Placebo
Study: NCT04827056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally, as individual films in the SL space.
Study: NCT05319951
Drug: Oral Rehydration Salts power (iii)
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
Study: NCT04341688
Drug: Gargle/Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 50 patients in six study groups. Group A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene®) for 20-30 seconds, thrice daily for 6 days.~Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (ActiveOxy®) for 20-30 seconds, thrice daily for 6 days.~Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated locally) for 20-30 seconds, thrice daily for 6 days.~Group D (n=10) patients will use 2% hypertonic saline (Plabottle®) gargle and nasal lavage for a similar time period.~Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days Whereas Group F (n=5) will comprise of negative controls, who will not use any gargles or nasal lavage during study period.
Study: NCT06145490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, oral intake
Study: NCT04586010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
Study: NCT04297033
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lovastatin 40mg/d 12m
Study: NCT06681870
Drug: ASP1893
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04297033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05760937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06623630
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care
Study: NCT06369298
Drug: JK07
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
Study: NCT06369298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT06521008
Drug: anti muscarinic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
Study: NCT06624956
Drug: glucose, insulin, and potassium (GIK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV.
Study: NCT06381141
Drug: CLN-619
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-MICA/MICB monoclonal antibody
Study: NCT06672939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06681922
Drug: Cyclophosphamide, Bortezomib, Abatacept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug given for prevention of Graft-versus-Host Disease (GvHD) following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Study: NCT06684041
Drug: HRS-5965 capsule placebo
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5965 capsule placebo
Study: NCT05035082
Drug: oral glucose-lowering medications (commercially available)
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration The doctor will give a prescription for the medicine and tell how to take it.
Study: NCT05020184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT06683638
Drug: Doxycycline 200mg daily for 14 days
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doxycycline will be taken as a single dose of 200mg daily, rather than the current CDC-recommended 100mg twice daily regimen for early syphilis. The duration will still be 14 days of therapy.
Study: NCT05636540
Drug: [18F]FluorThanatrace ([18F]FTT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
Study: NCT05331664
Drug: Prednisolone 1%
Normalized name: GENTAMICIN 0.3/PREDNISOLONE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
Study: NCT05527704
Drug: 0,9% Chloride Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL nebulized 0.9% NaCl administered for 30 min.
Study: NCT05062317
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by PO
Study: NCT05062317
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05667428
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
Study: NCT06378658
Drug: BAY2927088
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05094154
Drug: anti-pseudomonal cephalosporin
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
Study: NCT06624696
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
Study: NCT06626256
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06624878
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
Study: NCT05613426
Drug: Rosuvastatin 20 mg
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very early use of Rosuvastatin before primary PCI in anterior STEMI
Study: NCT05751226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05718687
Drug: GBT021601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
Study: NCT05347771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
Study: NCT06361238
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
Study: NCT05029726
Drug: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
Study: NCT05029726
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline in 30cc syringes administered using ESPB technique
Study: NCT05640232
Drug: CDE100 association
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental drug.
Study: NCT05640232
Drug: Buscopan® Composto association
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator.
Study: NCT05191862
Drug: PMR 135 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
Study: NCT05575804
Drug: pyrotinib+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
Study: NCT06522854
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet given orally every eight hours up to three times while mother is in labor
Study: NCT06693648
Drug: AMZ001 Diclofenac gel
Normalized name: diclofenac Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac gel applied once daily
Study: NCT06693648
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo gel applied once daily
Study: NCT06693674
Drug: Entresto Pill
Normalized name: Entresto Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
Study: NCT05173272
Drug: Neoadjuvant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
Study: NCT05260008
Drug: bupivacaine hydrochloride without epinephrine
Normalized name: bupivacaine hydrochloride / epinephrine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
Study: NCT05120349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
Study: NCT06511011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules for 6 weeks
Study: NCT06307080
Drug: Intravenous anti-PD-1 and chemotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous anti-PD-1 and chemotherapy
Study: NCT04749108
Drug: Induction chemotherapy - modified FOLFIRINOX regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
Study: NCT06041529
Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Study: NCT06041529
Drug: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Study: NCT05431582
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO 1 time a day with a glass (about 8 ounces) of water
Study: NCT05874219
Drug: Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention Sprayed 1 to 3 times /day
Study: NCT06693518
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
Study: NCT06693518
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran Etexilate 150 mg
Study: NCT04732416
Drug: HM15136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of HM15136/ High dose of HM15136, SC injection, weekly
Study: NCT05269134
Drug: Bacteriophage
Normalized name: bacteriophages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phage Therapy
Study: NCT05269134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05164952
Drug: Zoledronic Acid 4 MG
Normalized name: zoledronic acid 4 MG
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: (4 mg via 15-min infusion every 6 months) for 24 months
Study: NCT06632379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be assigned to identical appearing placebo
Study: NCT05272059
Drug: MHS552
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Study: NCT05272059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Study: NCT05496426
Drug: KL130008/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: KL130008 Drug: Placebo
Study: NCT05952219
Drug: D759+D745+D029+D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablet co-administration under fed condition
Study: NCT06256926
Drug: Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
Study: NCT06256926
Drug: Placebo product
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
Study: NCT05923905
Drug: FB1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/day
Study: NCT05923905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg/day
Study: NCT05795465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00002089
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06118099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection solution SC injection
Study: NCT04780932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg will be initiated at Day 8 (+/- 3 days) until week 42 (+/- week). The recommended dose is 10 mg once daily by oral administration
Study: NCT06130566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection solution SC injection
Study: NCT05668013
Drug: TEV-48574 Dose Regimen A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (sc) administration using a commercial sc infusion system
Study: NCT05931380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04884035
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
Study: NCT04884035
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
Study: NCT05159700
Drug: PRJ1-3024
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRJ1-3024 is provided as capsules and is administered orally once a day.
Study: NCT06108830
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
Study: NCT05727163
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 via HAI
Study: NCT05727163
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
Study: NCT05727163
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 intravenously
Study: NCT05727163
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
Study: NCT06427681
Drug: BH006 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
Study: NCT05740332
Drug: Alcohol hand sanitizer foam
Normalized name: BENZETHONIUM CHLORIDE 2.5 g in 1 L TOPICAL LIQUID [Sierra Soft Non-Alcohol Hand Sanitizer Foam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)
Study: NCT06171880
Drug: JLP-1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of JLP-1901
Study: NCT06171880
Drug: JC-001(active comparator)
Normalized name: eptacog alfa activated 0.001 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of JC-001(tenofovir)
Study: NCT05001217
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
Study: NCT05001217
Drug: Chinese herbal medicine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction
Study: NCT06672393
Drug: HS-10374-matched placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
Study: NCT06671509
Drug: YZJ-1139
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, 20 mg tablet
Study: NCT05032053
Drug: Antithrombotic drugs
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
Study: NCT06693362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
Study: NCT06693362
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
Study: NCT05857202
Drug: Analgesics, Opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
Study: NCT05857202
Drug: Analgesics, Non-Narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
Study: NCT06694935
Drug: QX1206
Approvals — FDA: no, EMA: no, PMDA: no
Description: QX1206 will be administered orally before bedtime
Study: NCT06688292
Drug: Actein effervescent 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis.
Study: NCT06686745
Drug: SIM0508 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.